Search results
Showing 16 to 30 of 148 results for multiple sclerosis
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)
Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults.
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)
Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis.
Evidence-based recommendations on natalizumab (Tysabri) for treating highly active relapsing–remitting multiple sclerosis in adults.
View recommendations for TA127Show all sections
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]
Suggested remit - To appraise the clinical and cost effectiveness of fingolimod within its marketing authorisation for treating relapsing multiple sclerosis in ...
In development [GID-TA10977] Expected publication date: TBC
Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]
Suggested remit: To appraise the clinical and cost effectiveness of natalizumab within its marketing authorisation for treating highly active relapsing-remittin...
In development [GID-TA11293] Expected publication date: 05 February 2025
This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.
icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)
NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .
Urinary incontinence in neurological disease: assessment and management (CG148)
This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.
Evidence-based recommendations on percutaneous venoplasty for chronic cerebrospinal venous insufficiency in people with multiple sclerosis. This involves inserting an inflatable balloon into veins in the neck and chest in an attempt to widen them.
View recommendations for IPG640Show all sections
with moderate to severe multiple sclerosis (MS) remain physically active. It supports CG186 and QS 108 statement 4: 'Adults...
Ublituximab for treating relapsing–remitting multiple sclerosis ID6350
In development [GID-TA11268] Expected publication date: TBC
Tolebrutinib for treating relapsing multiple sclerosis TS ID 11845
Awaiting development [GID-TA11333] Expected publication date: TBC